Protective role of intravesical BCG in COVID-19 severity

Simple item page
dc.contributor.authorGallegos, Héctor
dc.contributor.authorRojas, Pablo A.
dc.contributor.authorSepúlveda, Francisca
dc.contributor.authorZúñiga Avendaño, Álvaro Alfonso
dc.contributor.authorSan Francisco Reyes, Ignacio Felipe
dc.date.accessioned2021-04-12T12:09:52Z
dc.date.available2021-04-12T12:09:52Z
dc.date.issued2021
dc.date.updated2021-04-07T06:54:13Z
dc.description.abstractAbstract Objectives To establish the role of BCG instillations in the incidence and mortality of COVID-19. Patients and methods NMIBC patients in instillations with BCG (induction or maintenance) during 2019/2020 were included, establishing a COVID-19 group (with a diagnosis according to the national registry) and a control group (NO-COVID). The cumulative incidence (cases/total patients) and the case fatality rate (deaths/cases) were established, and compared with the national statistics for the same age group. T-test was used for continuous variables and Fisher's exact test for categorical variables. Results 175 patients were included. Eleven patients presented CIS (11/175, 6.3%), 84/175 (48.0%) Ta and 68/175 (38.9%) T1. Average number of instillations = 13.25 ± 7.4. One hundred sixty-seven patients (95.4%) had complete induction. Forty-three patients (cumulative incidence 24.6%) were diagnosed with COVID-19. There is no difference between COVID-19 and NO-COVID group in age, gender or proportion of maintenance completed. COVID-19 group fatality rate = 1/43 (2.3%). Accumulated Chilean incidence 70–79 years = 6.3%. Chilean fatality rate 70–79 years = 14%. Conclusions According to our results, patients with NMIBC submitted to instillations with BCG have a lower case-fatality rate than the national registry of patients between 70 and 79 years (2.3% vs. 14%, respectively). Intravesical BCG could decrease the mortality due to COVID-19, so instillation schemes should not be suspended in a pandemic.
dc.format.extent4 páginas
dc.identifier.citationBMC Urology. 2021 Mar 30;21(1):50
dc.identifier.doi10.1186/s12894-021-00823-6
dc.identifier.urihttps://doi.org/10.1186/s12894-021-00823-6
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/57628
dc.identifier.wosidWOS:000635126700001
dc.issue.numeroNo. 50
dc.language.isoen
dc.nota.accesoContenido completo
dc.pagina.final4
dc.pagina.inicio1
dc.revistaBMC Urologyes_ES
dc.rightsacceso abierto
dc.rights.holderThe Author(s)
dc.subjectCOVID-19es_ES
dc.subjectNon-muscle invasive bladder canceres_ES
dc.subjectIntravesical BCGes_ES
dc.subject.ddc616.2414
dc.subject.deweyMedicina y saludes_ES
dc.subject.ods03 Good health and well-being
dc.subject.odspa03 Salud y bienestar
dc.titleProtective role of intravesical BCG in COVID-19 severityes_ES
dc.typeartículo
dc.volumenVol. 21
sipa.codpersvinculados72399
sipa.codpersvinculados152729
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
12894_2021_Article_823.pdf
Size:
664.05 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
0 B
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Artículos de revistas